Monoclonal antibodies against frizzled

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9273139
APP PUB NO 20130295105A1
SERIAL NO

13800454

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ONCOMED PHARMACEUTICALS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Axelrod, Fumiko Takada Palo Alto, US 24 329
Gurney, Austin L San Francisco, US 2150 9828
Hoey, Timothy Charles Hillsborough, US 36 437
Mitra, Satyajit Sujit Kumar South Pasadena, US 11 148
Sato, Aaron Ken Burlingame, US 32 392
Satyal, Sanjeev H San Carlos, US 18 203

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 1, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00